Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Vilya launches out of Baker lab with $50 million

by Gina Vitale
September 1, 2022 | A version of this story appeared in Volume 100, Issue 31

Vilya, a start-up based on the work of David Baker and other scientists at the University of Washington’s Institute for Protein Design, has launched with $50 mil- lion in series A financing. Vilya says it will use computational approaches such as machine learning to design therapeutic peptides and other molecules that are between small molecules and antibodies in size. The molecules will have drug-like properties, including membrane permeability and the ability to disrupt interactions between proteins. Monod Bio, another Baker lab spin-out, recently received $25 million in seed funding.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.